Drug Development for Neurodegenerative Diseases--Second Annual marcus evans Conference. Advances in drug development for NDD and expediting discovery through novel compounds and sound clinical trials.
The Second Annual marcus evens Drug Development for Neurodegenerative Diseases Conference, held in Boston, included topics covering new therapeutic developments in the field of neurodegenerative diseases. This conference report highlights selected presentations on biomarkers for neurodegenerative diseases; novel approaches to therapy for neurodegenerative disorders, including targeting PKCepsilon in Alzheimer's disease, small-molecule therapeutics for neurogenesis, neureglins to promote neurorecovery, and updates on several investigational drugs; and progress in neurodegenerative disease research, including measuring microtubule dynamics in Parkinson's disease and drug delivery to the brain. Investigational drugs discussed include NNI-251 (NeuroNascent Inc), neuregulins including glial growth factor 2 (Acorda Therapeutics Inc), AL-108 (Allon Therapeutics Inc) and EVP-0962 (EnVivo Pharmaceuticals Inc).
Morimoto
Bruce
B
Allon Therapeutics, 506-1168 Hamilton Street, Vancouver, BC, V6B 2S2, Canada. bmorimoto@allontherapeutics.com
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D055808:Drug Discovery; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D055495:Neurogenesis / Q000187:drug effects
D015415:Biomarkers; D015507:Drugs, Investigational